Low CSF Amyloid-Beta Predicts Intracranial Hemorrhage in CAA Patients

Managing patients with cerebral amyloid angiopathy remains one of the most difficult challenges in vascular neurology, as the condition significantly elevates the risk of spontaneous lobar intracerebral hemorrhage [1]. This risk is particularly acute when patients present with comorbid atrial fibrillation, where the necessity of anticoagulation must be weighed against a high baseline potential for catastrophic bleeding [2]. While recent evidence suggests that left atrial appendage occlusion or carefully selected direct oral anticoagulants may offer some protection, the quality of evidence for these interventions remains limited [3, 4]. Current clinical guidelines emphasize the importance of identifying neuroimaging markers like cortical superficial siderosis to gauge risk, yet these features alone often fail to provide the precision needed for individualized treatment decisions [5, 6]. Furthermore, the presence of white matter hyperintensities and perivascular spaces on magnetic resonance imaging indicates a high burden of small vessel disease but lacks the specificity to predict the timing of future hemorrhagic events [7, 8]. A recent study investigates whether specific biochemical markers in the cerebrospinal fluid can provide the predictive clarity that has long eluded clinical practice.